At UCB, we come together everyday laser-focused on a simple question: How will this create value for people living with severe diseases? We are a global biopharmaceutical company committed to innovation to improve the lives of people with neurological and immunological diseases, finding solutions to meet their unique needs.
Sallie Cooke | Sallie.Cooke@ucb.com
Matt Franco | email@example.com
At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.
Castle Biosciences is a skin cancer diagnostics company focused on providing physicians and patients with personalized, clinically actionable genomic information enabling more accurate treatment plan decisions. From its formation in 2008, Castle Biosciences has applied emerging artificial intelligence techniques in molecular diagnostics to improve patient care and outcomes. Our DecisionDx family of molecular diagnostic tests have the ability to meaningfully impact how cancers are diagnosed and managed (castletestinfo.com).
DecisionDx®-Melanoma predicts risk of recurrence or metastasis that can inform decisions regarding sentinel lymph node biopsy and the intensity of follow-up, surveillance imaging, referral, and adjuvant therapy for patients with invasive cutaneous melanoma. The test uses tumor biology to provide an individual risk of melanoma recurrence beyond traditional factors such as AJCC staging criteria and integrates the 31-GEP score with clinicopathologic factors to provide a more precise and personalized risk of recurrence (i31-ROR) and sentinel lymph node positivity (i31-SLNB) prediction. DecisionDx-Melanoma is supported by consistent evidence in 30 publications including two meta-analyses showing Level 1 evidence classification.
We provide the most comprehensive gene expression profile (GEP) diagnostic workflow designed to aid in characterizing difficult-to-diagnose melanocytic lesions . Our diagnostic offering includes two tests, myPath® Melanoma and DecisionDx® DiffDx™-Melanoma, leveraging the strengths of both to provide a highly accurate, objective evaluation for a more confident and actionable patient management plan.
DecisionDx®-SCC predicts metastatic risk for patients with cutaneous squamous cell carcinoma who have one or more risk factors. The test complements factors commonly used for risk assessment in SCC. The incorporation of DecisionDx-SCC results with traditional risk factors provides additional risk prediction to better inform choices about treatment and follow-up care.
DecisionDx-UM predicts risk of metastasis for patients with uveal melanoma, a rare eye cancer. The test is standard of care in a majority of ocular oncology practices.
Castle Biosciences has active research and development programs for tests in other dermatologic diseases with high clinical need, including in patients with moderate to severe psoriasis, atopic dermatitis and related conditions. The company is based in Friendswood, Texas with laboratory operations in Phoenix, Arizona (www.CastleBiosciences.com).
Castle Biosciences, Inc. | Regional Business Director
Cell: 757-303-4465 | firstname.lastname@example.org
Incyte is a global biopharmaceutical company that is focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines.
Since 2002, Incyte has remained committed to the relentless pursuit of science that can improve the lives of patients, make a difference in healthcare and build sustainable value for our stakeholders. The Company is advancing a diversified portfolio of clinical candidates across Oncology and Inflammation & Autoimmunity.
Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.
Michelle Antonelli | email@example.com
Laura Eye | firstname.lastname@example.org
PRW Laboratories is central Virginia’s leading independent, full-service, dermatopathology laboratory. Our team of physicians includes both clinical dermatologists and surgical pathologists who are Board Certified in dermatopathology. The unique PRW model is that of a private practice/academic hybrid, whereby we not only provide routine diagnoses and second opinion consultations, but also participate in the education of residents and fellows. Some of our doctors are internationally recognized authors of the leading textbooks in the field. PRW’s experts provide timely and accurate diagnoses at significantly lower fees than traditional university-based laboratories.
Office Manager | Client Services
(o) 434-244-0162, option 2
AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across our Allergan Aesthetics portfolio.
Pamela Hamacher | email@example.com
LA ROCHE-POSAY: Recommended by 90,000 dermatologists worldwide[i], La Roche-Posay’s mission is to offer life-changing dermatological skincare. Created by a French pharmacist in 1975, the brand is now available in over 60 countries. It offers a unique range of daily skincare developed for every skin type to address various skin concerns and complement prescription treatments. At the center of the brand is the exclusive selenium-rich La Roche-Posay Thermal Spring Water, a core ingredient in its skincare formulas known for its soothing and antioxidant properties that is sourced from its Thermal Center in France, the first Dermatology Center in Europe. The products are developed using a strict safety and formulation charter with a minimal number of ingredients and are formulated at optimal concentrations. Additionally, La Roche-Posay products undergo stringent clinical testing for efficacy and safety with over 750+ studies and 25 years of extensive research, even on sensitive skin. The key La Roche-Posay product ranges are: Lipikar (dry skin), Anthelios (photoprotection), Effaclar (acne) and Toleriane (sensitive skin). [i] L’Oreal Barometer Study, Wave 3, Healthcare Market Worldwide
CeraVe: CeraVe was founded in 2005 when experts within the dermatology community recognized the relationship between ceramides, compromised skin barrier and skin conditions like acne, eczema, psoriasis, and xerosis. Developed with dermatologists, all CeraVe products are formulated with 3 essential ceramides (1, 3, & 6-II) to help maintain and restore the skin’s natural barrier, reinforcing healthy skin for all.
804-426-9918 | Barbara.firstname.lastname@example.org
Novartis is a leading global medicines company, using innovative science and digital technologies to create treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world. Find out more at https://www.novartis.us